Celgene Corporation (CELG) : Pioneer Investment Management Inc scooped up 145,532 additional shares in Celgene Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 10, 2016. The investment management firm now holds a total of 3,821,415 shares of Celgene Corporation which is valued at $382,752,926.Celgene Corporation makes up approximately 1.47% of Pioneer Investment Management Inc’s portfolio.
Other Hedge Funds, Including , Finemark National Bank Trust reduced its stake in CELG by selling 315 shares or 1.94% in the most recent quarter. The Hedge Fund company now holds 15,924 shares of CELG which is valued at $1,594,948. Celgene Corporation makes up approx 0.19% of Finemark National Bank Trust’s portfolio.Mitchell Capital Management Co boosted its stake in CELG in the latest quarter, The investment management firm added 1,804 additional shares and now holds a total of 91,550 shares of Celgene Corporation which is valued at $9,177,888. Celgene Corporation makes up approx 3.21% of Mitchell Capital Management Co’s portfolio.Linscomb Williams reduced its stake in CELG by selling 55 shares or 1.2% in the most recent quarter. The Hedge Fund company now holds 4,517 shares of CELG which is valued at $452,829. Celgene Corporation makes up approx 0.05% of Linscomb Williams’s portfolio.State Board Of Administration Of Florida Retirement System reduced its stake in CELG by selling 17,622 shares or 1.76% in the most recent quarter. The Hedge Fund company now holds 982,089 shares of CELG which is valued at $98,454,422. Celgene Corporation makes up approx 0.38% of State Board Of Administration Of Florida Retirement System’s portfolio.Rothschild Investment Corp Il boosted its stake in CELG in the latest quarter, The investment management firm added 245 additional shares and now holds a total of 87,313 shares of Celgene Corporation which is valued at $9,029,037. Celgene Corporation makes up approx 1.16% of Rothschild Investment Corp Il’s portfolio.
Celgene Corporation opened for trading at $99.99 and hit $101.8 on the upside on Monday, eventually ending the session at $101.57, with a gain of 1.41% or 1.41 points. The heightened volatility saw the trading volume jump to 24,29,016 shares. Company has a market cap of $78,676 M.
On the company’s financial health, Celgene Corporation reported $1.32 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $1.27. The company had revenue of $2511.60 million for the quarter, compared to analysts expectations of $2577.08 million. The company’s revenue was up 20.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.07 EPS.
Many Wall Street Analysts have commented on Celgene Corporation. Company shares were Reiterated by Sun Trust Rbsn Humphrey on Apr 29, 2016 to “Buy”, Firm has raised the Price Target to $ 147 from a previous price target of $145 .Citigroup Initiated Celgene Corporation on Feb 25, 2016 to “Buy”, Price Target of the shares are set at $130.
Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Companys primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.